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ABSTRACT 47 
Human T-cell lymphotropic virus (HTLV) -1 was the first human retrovirus to be associated to 48 
cancer, namely Adult T-cell Leukemia (ATL), but its pathogenesis remains enigmatic, since 49 
only a minority of infected individuals develops either ATL or the neuroinflammatory disorder 50 
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). A functional FAS -51 
670 polymorphism in an interferon (IFN)-regulated STAT1-binding site has been associated 52 
to both ATL and HAM/TSP susceptibility. Fashi T stem cell memory (Tscm) cells have been 53 
identified as the hierarchical apex of ATL, but have not been investigated in HAM/TSP. In 54 
addition, both FAS and STAT1 have been identified in an IFN-inducible HAM/TSP gene 55 
signature, but its pathobiological significance remains unclear. We comprehensively 56 
explored Fas expression (protein/mRNA) and function in lymphocyte activation, apoptosis, 57 
proliferation and transcriptome, in PBMC from a total of 47 HAM/TSP patients, 40 58 
asymptomatic HTLV-1-infected individuals (AC) and 58 HTLV-1 -uninfected healthy controls.  59 
Fas surface expression followed a two-step increase from HC to AC and from AC to 60 
HAM/TSP. In HAM/TSP, Fas levels correlated positively to lymphocyte activation markers, 61 
but negatively to age of onset, linking Fashi cells to earlier, more aggressive disease. 62 
Surprisingly, increased lymphocyte Fas expression in HAM/TSP was linked to decreased 63 
apoptosis and increased lymphoproliferation upon in vitro culture, but not to proviral load. 64 
This Fashi phenotype is HAM/TSP-specific, since both ex vivo and in vitro Fas expression 65 
was increased as compared to multiple sclerosis another neuroinflammatory disorder. To 66 
elucidate the molecular mechanism underlying non-apoptotic Fas signalling in HAM/TSP, we 67 
combined transcriptome analysis with functional assays, i.e. blocking vs. triggering Fas 68 
receptor in vitro with antagonist and agonist- anti-Fas mAb, respectively. Treatment with 69 
agonist anti-Fas mAb restored apoptosis, indicating biased but not defective Fas signalling in 70 
HAM/TSP. In silico analysis revealed biased Fas signalling towards proliferation and 71 
inflammation, driven by RelA/NF-kB. Correlation of Fas transcript levels with proliferation 72 
(but not apoptosis) was confirmed in HAM/TSP ex vivo transcriptomes. In conclusion, we 73 
demonstrated a two-step increase in Fas expression, revealing a unique Fashi lymphocyte 74 
phenotype in HAM/TSP, distinguishable from multiple sclerosis. Non-apoptotic Fas signalling 75 
might fuel HAM/TSP pathogenesis, through increased lymphoproliferation, inflammation and 76 
early age of onset.  77 
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INTRODUCTION 143 
Human T-lymphotropic virus 1 (HTLV-1) is an exogenous human retrovirus infecting 5-10 144 
million people worldwide, mostly in HTLV-1 endemic regions.1 While a majority of HTLV-1 145 
carriers remain asymptomatic (AC) lifelong, a minority (0.25-3%) progresses to either adult 146 
T-cell leukemia/lymphoma (ATL) or HTLV-1-associated myelopathy/tropical spastic 147 
paraparesis (HAM/TSP)2,3. Thirty years after its discovery it is still enigmatic how a single 148 
retrovirus causes either fatal hematologic malignancy or neuroinflammation in a small subset 149 
of infected individuals. Among factors that allow to discriminate between the three clinical 150 
groups (AC, ATL, HAM/TSP), humoral immunity,4 proteome5,6 have been described. In 151 
agreement with a role for immune activation 4,6-9 in HAM/TSP pathogenesis, promising 152 
preclinical results were obtained with Jak kinase and NFkB inhibitors.10,11 Very few drugs, e.g. 153 
valproate, have actually overcome the hurdle in transition from preclinical results12 to clinical trial in 154 
HAM/TSP.13 Taken together, these studies point at a possible clinical benefit of decreasing 155 
lymphoproliferation and/or increasing apoptosis in HAM/TSP patients. HTLV-1-infected cells are 156 
driven towards spontaneous lymphoproliferation and oligoclonal expansion.14,15 On the other 157 
hand, apoptosis (programmed cell death) is known to play a role in controlling 158 
lymphoproliferation in autoimmune diseases.16,17 Fas (TNFRSF6/CD95/APO-1) is a death-159 
domain containing receptor of the tumor necrosis factor (TNF) receptor superfamily inducing 160 
apoptosis17, when ligated by Fas ligand (FasL) or agonist antibodies.18 Fas-FasL signalling is 161 
proposed to play a role in both autoimmune and infectious diseases.17 In multiple sclerosis 162 
(MS) patients, increased Fas expression has since long been known,19 while resistance of T 163 
cells to Fas-mediated apoptosis has been linked to MS.20 In HTLV-1 infection, a wealth of 164 
data is available on pro- and anti-apoptotic effects of HTLV-1 infection, mainly its proto-165 
oncogene Tax.21 In the context of HAM/TSP immunopathogenesis, a role for Fas-FasL in the 166 
down-regulation of immune response in the CNS has been suggested.22 Previous studies on 167 
Fas in HAM/TSP have shown increased levels of soluble Fas in serum,23,24 and CSF,24 as 168 
well as surface expression in CD8 cells.25 A systems biology approach identified FAS (but 169 
not FASL) as part of an IFN-regulated gene signature in HAM/TSP patients.7 In addition, 170 
immunogenetic data revealed that a functional FAS -670 gene polymorphism is associated 171 
to both ATL26 and HAM/TSP27 disease susceptibility. Therefore, we hypothesized that 172 
lymphocyte Fas expression and/or apoptosis may reflect clinical status in HAM/TSP patients. 173 
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PATIENTS AND METHODS 174 
A flow chart diagram (Figure 1) provides an overview of the study outline, cohorts, as well as 175 
ex vivo, in vitro and in silico experimental approach, while patient information and sample 176 
use is summarized in Table 1. 177 
HAM/TSP patients (n=47, 66.0% female, mean age 50.2±11.5 years, mean disease duration 178 
5.6±4.0 y (range 0.8-14 y), EDSS range 3-7 (mean 5.1±1.2)) were recruited from three 179 
endemic regions (Sao Paulo and Salvador-Bahia, Brazil and Lima, Peru) following written 180 
informed consent. Age- and gender-matched HTLV-1-infected asymptomatic carriers (AC, 181 
n=40) and uninfected healthy controls (HC, n=58) from the same endemic regions were 182 
included in the study. The study was approved by the Ethics Committees of University of 183 
Sao Paulo and FIOCRUZ-Bahia in Brazil and Universidad Peruana Cayetano Heredia in 184 
Lima, Peru. Diagnosis of HAM/TSP was according to WHO criteria29 Antibodies to HTLV-1/2 185 
were investigated by diagnostic ELISA (Murex, Abbott, Germany; Bioelisa HTLV-1+2, Biokit 186 
Spain) and confirmed by Western blot capable of discriminating between HTLV-1 and HTLV-187 
2 (HTLV Blot 2.4, Genelab, Singapore). All HTLV-1-infected individuals were seronegative 188 
for HTLV-2 and HIV. For comparison with another neuroinflammatory disorder, data from MS 189 
patients (recruited during our previous study30) was used. 190 
Isolation of PBMC and in vitro cell culture  191 
PBMC isolated from 5-10ml of heparinized venous blood by Ficoll-Hypaque density gradient 192 
centrifugation (Sigma-Aldrich) were washed twice with PBS and were plated in 24-well tissue 193 
culture plates (Costar, NY) at 4×106 cells/ml and incubated at 37°C and 5% CO2 in 194 
RPMI1640 medium supplemented with 2mM L-glutamine, gentamycin (50μg/ml) and 10% 195 
heat-inactivated fetal calf serum (Gibco, NY). 196 
HTLV-1 p19 and Proviral load quantification 197 
HTLV-1 matrix protein p19 was quantified in cell-free supernatant of HAM/TSP patients’ 198 
PBMC and AC and HC using RetroTek HTLV-1/2 p19 Antigen ELISA kit (ZeptoMetrix) after 199 
48h of in vitro culture. Proviral load (PVL, i.e. viral DNA integrated into the host genome) in 200 
HAM/TSP patients and AC was quantified as published.30,31 201 
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Quantification of cell surface markers by flow cytometry 202 
For phenotypic analysis, PBMC were resuspended at a density of 200,000 cells in 50µL of 203 
1% BSA, 0.1% NaN3 in PBS (+20% human serum to block Fc receptors) and incubated for 204 
30min on ice with mAbs specific for CD3, CD4, CD8, , CD80, CD86, CD95/Fas,  HLA-DR 205 
and corresponding isotype controls (BD Biosciences). For total Fas surface quantification 206 
and apoptosis, a minimum of 100,000 events/sample were stained and acquired with 207 
FACSort and FACSCanto II flow cytometers (BD Biosciences) and analyzed using CellQuest 208 
and Diva software, respectively.  209 
Proliferation and Apoptotic assays 210 
Lymphoproliferation was quantified by [3H]-thymidine incorporation and flow cytometry (as 211 
described in30,32), the initial stage of apoptosis was analyzed using annexin V staining, 212 
whereas cells in the late/final stage of apoptosis were identified as a sub-diploid population 213 
by flow cytometry. Nuclear fragmentation was quantified by fluorescence microscopy and 214 
ELISA (Cell Death Detection plus, Boehringer-Mannheim, Germany). 215 
Fas triggering and blocking experiments 216 
PBMC were cultured as above for 48h in the presence or absence of agonist or antagonist 217 
anti-Fas mAbs (1µg/ml, Alexis Biochemicals) or anti-CD3 mAb (Butantan Institute, Sao 218 
Paulo-Brazil) as a positive control for in vitro apoptosis. 219 
Microarray analysis 220 
Total RNA was extracted from PBMC according to manufacturer’s protocol (QIAgen, Venlo, 221 
The Netherlands). Whole genome microarray was performed at VIB Nucleomics (Leuven, 222 
Belgium) using GeneChip® Human Gene1.0 ST Array (Affymetrix, Santa Clara, CA), 223 
according to manufacturer’s specifications. Data was analyzed using Bioconductor limma 224 
package (Smyth, GK, 2005), using a moderated t-test, resulting p-values were corrected for 225 
genome-wide testing (5% FDR). All microarray raw data are available at Gene Expression 226 
Omnibus database (GEO, http://www.ncbi.nlm.nih.gov/geo/) series accession number 227 
GSE82160.  228 
Statistical analysis  229 
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The use of parametric (t-test, Pearson correlation) or non-parametric (Mann-Whitney or 230 
Spearman rank correlation) tests was based upon normal distribution as determined by 231 
Kolmogorov-Smirnov test (all GraphPad Prism v5.0 or v6.0). A p-value of <0.05 was 232 
considered significant for all statistical tests. Transcriptome-wide correlation of FAS mRNA 233 
expression levels was calculated using Spearman rank correlation test, with stringent 234 
correction for multiple testing (5% FDR). 235 
RESULTS 236 
A two-step increase in ex vivo total lymphocyte Fas surface expression, in HTLV-1-237 
infected individuals and HAM/TSP patients, distinguishable from MS patients. 238 
In a first cohort, we quantified surface Fas levels as well as apoptosis by flow cytometry, ex 239 
vivo in PBMC from HC (HTLV-1-negative, n=14), AC (HTLV-1-positive, n=30) and HAM/TSP 240 
patients (n=18). We observed a significant increase in ex vivo levels (%) of Fas+ lymphocyte 241 
in AC (1.8-fold) as well as in HAM/TSP patients (2.1-fold), when compared to HC (Kruskal-242 
Wallis, Dunn’s post-test, p<0.05, p<0.001; respectively, Figure 2A). Moreover, lymphocyte 243 
Fas level on a per-cell basis, expressed as mean fluorescence intensity (MFI), revealed an 244 
8-fold increase in AC and a striking 19-fold increase in HAM/TSP (Kruskal-Wallis, Dunn’s 245 
post-test, p<0.001), when compared to HC, but also when compared to AC (p<0.05, Figure 246 
2B), indicating that clinical progression to HAM/TSP is characterized by a predominant Fashi 247 
lymphocyte population, possibly primed for apoptosis. To confirm the two-step model of Fas 248 
increase, we performed a post-hoc test for linear trend, which was highly significant 249 
(p<0.001) for both % (slope 18.8) and MFI (slope 64.1).  250 
Next, we proceeded to examine Fas expression in  CD4, CD8 and B cell subsets in more 251 
detail in an independent second cohort of HC (n=7), AC (n=6) and HAM/TSP patients (n=9). 252 
There was no difference in the percentage of cells expressing Fas between the three clinical 253 
groups for either cellular subset (Figure 2C.). However, we observed a small but significant 254 
linear trend in Fas MFI of CD4+ T cells with clinical status (ANOVA p=0.067, post-test for 255 
linear trend p<0.05, slope=349.2), but not in CD8+ T cells or B cells. Thus, the strongest 256 
difference between the clinical groups was in total Fas+ lymphocytes rather than specific 257 
subsets, revealing a Fashi phenotype in HAM/TSP. To verify if this Fashi phenotype might be 258 
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shared among neuroinflammatory disorders, we compared Fas expression between 259 
HAM/TSP and multiple sclerosis (MS) patients. As shown in Figure 2D, we found a 260 
significant 1.6-fold increase in % of ex vivo Fas+ lymphocytes in HAM/TSP (Mann Whitney, 261 
p=0.03), as well as a 2.4-fold increase in Fas MFI, which approached statistical significance 262 
(Mann Whitney, p=0.08).  263 
Finally, ex vivo spontaneous apoptosis in HAM/TSP and AC, as measured by DNA 264 
degradation, (quantified as sub-diploid cells in flow cytometry) occurred at very low levels 265 
(<0.2% of PBMC, data not shown). Therefore, we questioned if the observed ex vivo 266 
increase in lymphocyte Fas surface expression in HAM/TSP reflected the immunological, 267 
virological or clinical status of HAM/TSP patients, rather than an apoptosis-prone status. 268 
Ex vivo lymphocyte Fas surface expression correlates to immune activation markers 269 
in HAM/TSP  270 
To explore possible clinical relevance of this increased lymphocyte Fas in HAM/TSP 271 
patients, we correlated ex vivo Fas surface expression to patient demographic and clinical 272 
data. We observed that, in HAM/TSP, ex vivo lymphocyte Fas (% or MFI) was not correlated 273 
to age, gender, disease duration or severity. In addition, ex vivo lymphocyte Fas was not 274 
significantly correlated to PVL in AC or HAM/TSP (p>0.05). However, ex vivo Fas levels (%) 275 
correlated significantly to lymphocyte activation markers HLA-DR and CD86 (Figure 3A-B), 276 
implying that increased Fas expression may be coupled to immune activation and/or 277 
inflammation in HAM/TSP.  278 
In vitro Fas+ lymphocyte levels correlate negatively to both age of onset and in vitro 279 
apoptosis: a selective defect in HAM/TSP patients? 280 
Upon quantification of in vitro Fas+ lymphocyte expression in HC, AC and HAM/TSP patients 281 
by flow cytometry, we again observed a two-step increase in % Fas+ lymphocytes: 2-fold in 282 
AC and 3.4-fold in HAM/TSP vs. HC (Post-test for linear trend, p=0.0001, slope=27.0) 283 
(Figure 4A). In HAM/TSP, in vitro Fas levels per-cell (MFI) were even more pronounced, with 284 
an 8-fold increase over HC. Hence, clinical status impacts both ex vivo (Figure 2A-B) and in 285 
vitro (Figure 4A) Fas expression. In addition, Fas in vitro levels showed a significant negative 286 
correlation to age of disease onset in HAM/TSP patients (p=0.019, Pearson’s r =-0.69, n=11) 287 
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(Figure 4B), but not to age, disease duration and gender, suggesting Fashi phenotype 288 
predisposes to earlier, aggressive disease manifestation. Further, in vitro Fas expression 289 
neither correlated to viral p19 protein level (p=0.41), nor to PVL (p=0.14) in HTLV-1-infected 290 
individuals (data not shown).  291 
In agreement with its role as a death receptor in immune homeostasis, Fas surface 292 
expression positively correlates with spontaneous in vitro apoptosis in HC, while this 293 
correlation was lost in AC (data not shown). Surprisingly, ex vivo Fas expression correlated 294 
negatively (Supplementary Figure 1) to spontaneous in vitro apoptosis in HAM/TSP. 295 
Furthermore, in vitro Fas level (MFI) also correlates negatively to lymphocyte apoptosis in 296 
HAM/TSP (Figure 5A). This negative correlation was confirmed by fluorescence microscopy. 297 
As shown in Figure 5B, Fashi cells are negative for annexin V staining and display normal 298 
nuclear morphology, whereas Faslo cells were seen to undergo apoptosis by both annexin V 299 
staining and nuclear condensation/fragmentation, occasionally triggering phagocytosis by 300 
macrophages, emphasizing their apoptotic nature. Since resistance to Fas induced 301 
apoptosis has been observed in vitro in lymphocytes from MS patients,34 we compared in 302 
vitro lymphocyte Fas expression and apoptosis between HAM/TSP and MS patients. As 303 
shown in Figure 5C, there was a significant increase (2.4-fold, Mann-Whitney test, p=0.019) 304 
in Fas MFI in HAM/TSP as compared to MS patients, but not apoptosis (as measured by 305 
annexin V staining, Mann-Whitney test, p=0.84). In contrast to HAM/TSP, no correlation was 306 
observed between Fas MFI and apoptotic cells in MS patients (p=0.35, data not shown). 307 
Taken together, the significant negative correlations between ex vivo and in vitro Fas 308 
lymphocyte expression and in vitro apoptosis observed only in HAM/TSP, suggest a possible 309 
selective defect in Fas-mediated apoptosis. Hence, we next aimed to comprehensively 310 
explore non-apoptotic Fas signalling in HAM/TSP. 311 
Fas expression positively correlates to lymphoproliferation in vitro and ex vivo in 312 
HAM/TSP 313 
We quantified in vitro spontaneous lymphoproliferation by [3H]-thymidine incorporation in 314 
HAM/TSP patients. Surprisingly, we found that Fas expression positively correlates to 315 
spontaneous lymphoproliferation in vitro (Figure 6A), which might imply that the observed 316 
defect in Fas-mediated pro-apoptotic signalling in HAM/TSP might be explained as a bias in 317 
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Fas signalling towards proliferation rather than apoptosis. Therefore, we hypothesized that 318 
Fashi cells might be already proliferating in vivo in HAM/TSP although at very low level. We 319 
thus extended our previously described27 sensitive flow cytometry assay to quantify Fas+ 320 
diploid vs. tetraploid (proliferating) lymphocytes ex vivo in HAM/TSP patients, stained 321 
immediately after PBMC isolation, without in vitro culture. As shown in Figure 6B, virtually all 322 
of the proliferating cells were Fashi (99.2±0.8%), as compared to non-proliferating 323 
lymphocytes (69.4±5.9%, Paired t test, p=0.0082). 324 
Stimulation with agonist Fas mAb in vitro can trigger apoptotic signalling in HAM/TSP 325 
We then examined if this apparent defect in Fas-mediated apoptosis might be reversible by 326 
stimulating with agonist anti-Fas mAb, and if blocking with antagonist anti-Fas mAb could 327 
reveal ongoing Fas-FasL signalling in HAM/TSP. Hence, we treated PBMC in vitro with anti-328 
Fas mAb (agonist or antagonist) or anti-CD3 mAb as a positive control. No decrease in 329 
spontaneous apoptosis was observed upon treatment with antagonist anti-Fas mAb, 330 
confirming our hypothesis of inactive Fas-FasL signalling in vitro in HAM/TSP. Interestingly, 331 
treatment with agonist anti-Fas mAb resulted in significantly increased apoptosis (1.7-fold, 332 
p<0.05), similar to treatment with anti-CD3 mAb (positive control, 1.8-fold, p<0.01) (Figure 333 
7A). These results imply that agonist anti-Fas mAb treatment can restore the apparent 334 
defect in apoptosis in HAM/TSP, at least in vitro.  335 
Systems analysis of gene expression profiles upon Fas triggering vs. Fas blocking in 336 
HAM/TSP 337 
Considering the significant correlation between in vitro Fas expression to age of onset in 338 
HAM/TSP, we resorted to genome-wide transcriptional analysis of PBMC treated in vitro with 339 
agonist or antagonist Fas mAb, to explore the broad pro/anti-apoptotic, inflammatory, 340 
proliferative and immunoregulatory Fas signalling pathways specifically triggered in 341 
HAM/TSP. Microarray analysis revealed that in vitro treatment with agonist anti-Fas mAb, 342 
significantly down-regulated 190 genes and up-regulated 59 genes (Supplementary Table 343 
1A and B), while treatment with antagonist anti-Fas mAb down-regulated 38 genes and up-344 
regulated 18 genes (Supplementary Table 1C and D). Thus, triggering Fas signalling effects 345 
a broader gene spectrum than inhibiting it. This was also evident from Ingenuity® pathway 346 
analysis (IPA), since no biological functions were significantly associated with antagonist 347 
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anti-Fas mAb treatment, whereas treatment with agonist anti-Fas mAb resulted in 22 348 
significantly associated biological functions (5% FDR-adjusted and a stringent cut-off of at 349 
least five enriched molecules per pathway) (Supplementary Table 2). The top 10 biological 350 
functions activated by agonist anti-Fas mAb (Supplementary Table 2), highlight cellular 351 
migration, especially of myeloid cells. In addition, IPA network analysis (Figure 7B) of Fas-352 
triggered gene expression reveals a central role for NFkB pro-survival signalling, connecting 353 
several up-regulated proliferative and inflammatory molecules (TNF, JNK, RNA Polymerase 354 
II, POLR2D, HIST1H3A, HIST1H2AB) as well as down-regulated anti-proliferative genes 355 
(L3MBTL2, CARD6). This central role for NFkB signalling was confirmed by Ingenuity 356 
upstream regulator analysis, identifying RelA as the top upstream regulatory molecule upon 357 
triggering Fas signalling (target genes: BCL2A1, CASR, CXCL3, ICAM1, L3MBTL2, PTGES, 358 
TGM2, TNF and TPMT; p= 0.000032). Again, blocking Fas signalling did not yield any 359 
significantly enriched upstream regulators (using the same stringent cut-off of five enriched 360 
molecules/pathway, data not shown). 361 
Genome-wide correlation of ex vivo Fas RNA levels in HAM/TSP confirms a 362 
significant association to proliferation but not apoptosis 363 
Finally, we used a pathway-based data mining approach, to test our hypothesis of biased 364 
Fas signalling, and to possibly extend our findings by including additional pro- and anti-365 
apoptotic genes (e.g. TRAIL, cFlip, etc.). For this purpose, we explored possible interactions 366 
of Fas mRNA within the ex vivo global gene expression profile in PBMC of HAM/TSP 367 
patients (n=6). Using transcriptome-wide correlation, 4554 genes significantly correlated to 368 
Fas transcript levels (Supplementary Table 3), after stringent FDR-correction for multiple 369 
testing. Using annotated Ingenuity pathways, we found a significant enrichment for 370 
proliferation-related genes (159 of 4554 genes, p=0.023). However, apoptosis, as defined by 371 
IPA, was not enriched amongst the ex vivo Fas-correlating genes (71 genes out of 4554 372 
genes, p=0.10). 373 
DISCUSSION 374 
In this study, we combined ex vivo, in vitro and systems analysis of Fas expression with 375 
functional apoptosis and proliferation assays, thereby providing an all-inclusive approach of 376 
the biological and clinical relevance of Fas signalling in HAM/TSP. We observed a two-step 377 
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increase in ex vivo Fas expression: first, a greater percentage of Fas+ lymphocytes upon 378 
HTLV-1 infection and second, a strong increase in expression of the death receptor at the 379 
single-cell level upon HAM/TSP disease progression. In addition, for the first time, we 380 
demonstrate that Fas expression correlates negatively to apoptosis and age of onset, but 381 
positively to immune activation and lymphoproliferation. 382 
The most surprising finding of this study is a selective defect in Fas-mediated apoptosis in 383 
HAM/TSP patients. First, both ex vivo and in vitro Fas levels negatively correlated to in vitro 384 
apoptosis (Figure 5A and Supplementary Figure 1). Second, by fluorescence microscopy 385 
(Figure 5B), we document that Faslo but not Fashi cells preferentially undergo apoptosis in 386 
vitro. Third, in vitro treatment of PBMC with agonist anti-Fas mAb, but not antagonist anti-387 
Fas mAb, was able to trigger apoptosis and restore the selective defect in HAM/TSP 388 
patients. Fourth, in silico analysis of the HAM/TSP transcriptome revealed a large number of 389 
transcripts (>4500) significantly correlating to Fas mRNA level, but are not enriched for 390 
apoptotic pathways. Taking together, our data indicate that the death receptor is fully 391 
functional in HAM/TSP, and not in a dormant state but skewed towards other biological 392 
pathways. Similar to our observation in HAM/TSP, increased Fas35 and resistance to Fas-393 
triggered apoptosis36 has been reported in MS, which was also supported by gene 394 
expression profiling.37 Nevertheless, our data reveal that the Fashi phenotype is HAM/TSP-395 
specific, since Fas expression was increased both ex vivo and in vitro, as compared to MS 396 
patients. Strikingly, the increase in non-apoptotic Fas receptor is also negatively correlated 397 
to age of disease onset in HAM/TSP (Figure 4B), rendering Fas as a clinically relevant 398 
molecule. It should be stated, however, that formal demonstration of the possible clinical 399 
utility of Fas expression or Fas downstream signalling targets as biomarker(s) in HAM/TSP 400 
will require confirmation of our findings in prospective cohort studies with a long-term clinical 401 
follow-up. In addition, agonist anti-Fas mAb, although restoring the defect in apoptosis in 402 
HAM/TSP, would not be a therapeutic option given that anti-Fas mAb therapy caused liver 403 
injury and lethality in mice.38 In the absence of clinical benefit of antiretrovirals in HAM/TSP, 404 
immunomodulatory options include IFN-α/β, glucocorticoids, cyclosporine and ascorbic 405 
acid.32,39,40 We previously demonstrated IFN-β can restore defective B cell CD86 up-406 
regulation in HAM/TSP.30 As in MS, defective Fas-mediated apoptosis in HAM/TSP patients 407 
may be overcome by IFN-β therapy.41,42 In addition to IFN therapy, our in silico analysis 408 
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might reveal novel treatment options. As shown in Figure 7B, a molecular network elegantly 409 
describes the interplay between the molecular players of apoptosis (CARD6, caspases), 410 
proliferation (POLR2D, L3MBTL2) and inflammation (TNF, JNK), with a central role for 411 
NFkB. Therefore, our data confirm and extend the findings of Oh et al.11 and Talledo et al.,9 412 
who pointed at the importance of NFkB signalling in HAM/TSP from a pharmacological and 413 
immunogenetic perspective. Furthermore, our Fas-triggered gene expression in HAM/TSP 414 
reveals the same upstream regulator (Rel A), which is associated to active disease in MS.37 415 
Thus, transcriptomics can reveal neuroinflammatory disorders sharing analogous biological 416 
pathways, indicating approved MS drugs to be considered in HAM/TSP, but also allow the 417 
identification of possible novel therapeutic targets, e.g. TGM2 or L3MBTL2 (Figure 7B). 418 
Regarding HAM/TSP pathogenesis, both genetic and environmental triggers have been 419 
suggested.43 Interestingly, in a large cohort in the same endemic area (Salvador-Bahia), a 420 
city with Afro-descendent demography, probable (but not definite) HAM/TSP occurred in 421 
31% of AC during 8-year follow-up,44 which suggests lifetime risk in this population is 10-fold 422 
higher than previously reported.43 As for environmental factors, co-infection with Gram-423 
positive bacteria, as in infective dermatitis, has been shown to trigger early HAM/TSP in 424 
children from the same endemic area.45,46 Concerning genetics, a single FAS -670 425 
polymorphism has been associated to both ATL26 and HAM/TSP27 susceptibility. Since this 426 
polymorphism also determined CD4 Tscm levels in a genome-wide twin study (Khouri et al, 427 
submitted), the proliferative, non-apoptotic Fashi cells in HAM/TSP are reminiscent of a Tscm 428 
phenotype,47 as outlined in Figure 8. However, since CD4 or CD8 Tscm represent only a 429 
minor subset of Fas+ lymphocytes28, a Tscm origin of Fashi cells is not likely, considering the 430 
two-step increase we observed both ex vivo and in vitro (Figures 2A-B and 4A), first in AC 431 
and second in HAM/TSP.  432 
Non-apoptotic Fas signalling towards proliferation has been previously demonstrated,48,49 433 
while Tax gene expression and cell cycling but not cell death are selected during HTLV-1 434 
infection in vivo.50 Tax mediates its anti-apoptotic activity by activating the NFkB pathway,51 435 
associating NFkB to cell survival and inflammation, similar to our in silico findings. In 436 
addition, Tax-deregulated autophagy and cFLIP expression are responsible for resistance to 437 
apoptosis in vitro,52 in agreement with our ex vivo and in vitro results. In contrast, many viral 438 
infections are associated with heightened apoptosis. The most striking example is HIV,53 439 
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which manipulates apoptotic pathways to enable efficient viral replication.54 In the case of 440 
HTLV-1, in vitro culture triggers viral protein synthesis and subsequent cytokine-driven 441 
lymphoproliferation.14 However, Fas did not correlate to PVL, similar to25 and two other 442 
published cohorts (p>0.5 for test and training sets).7 Interestingly, PVL also did not correlate 443 
to apoptosis or age of disease onset, in contrast to Fas. A previous larger study with 444 
sufficient statistical power also demonstrated PVL does not correlate to age of onset in 445 
HAM/TSP.55 Furthermore, viral p19 protein levels did not correlate to Fas in our cohort. 446 
Taken together, increased Fas levels in HAM/TSP appear to be driven by a IFN/STAT1 axis, 447 
either genetically27 or environmentally45 linked, rather than by the virus itself, suggesting the 448 
role of Fas in HAM/TSP pathogenesis is independent of PVL. Therefore, it is tempting to 449 
speculate that a similar IFN/STAT1 signalling pathway might underlie the suggested 450 
deleterious role of CD80+ B cells, correlating positively to disease severity, also independent 451 
of PVL.30  452 
In conclusion, our results suggest defective Fas-mediated apoptosis is linked to early 453 
disease onset and might be an additional factor in HAM/TSP pathogenesis, independent of 454 
PVL. Triggering Fas signalling, rather than inhibiting it, induces a specific gene set with a 455 
central role for NFkB pro-survival signalling. Thus, our integrated ex vivo, in vitro, in silico 456 
approach identifies biased pro-inflammatory and proliferative Fas signalling in HAM/TSP, 457 
revealing possible novel therapeutic targets.  458 
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Figure legends 621 
Figure 1. Schematic representation of the methodology (ex vivo, in vitro and in silico 622 
approaches). 623 
 624 
Figure 2. Ex vivo lymphocyte Fas surface expression in HTLV-1-infected individuals, 625 
HAM/TSP and MS patients. Using flow cytometry, Fas levels as % (A) and MFI (mean 626 
fluorescence intensity on a per cell basis) (B) were quantified in HC, AC and HAM/TSP 627 
patients. (*p<0.05, **p<0.01, ***p<0.001; Kruskal-Wallis, with Dunn’s multiple comparison 628 
post-test). (C) Fas expression in CD4, CD8 and B cells was quantified in ex vivo PBMCs in 629 
HC, AC and HAM/TSP patients (ANOVA, p=0.067, post-test for linear trend p<0.05). (D) Ex 630 
vivo Fas levels (% and MFI) are compared between neuroinflammatory diseases HAM/TSP 631 
and MS (Mann Whitney test, *p<0.05). 632 
 633 
Figure 3. Increased ex vivo lymphocyte Fas surface expression in HAM/TSP patients 634 
correlates with activation markers. Positive correlation between the percentage of Fas+ 635 
lymphocytes and (A) HLA-DR+ (*p=0.039, Spearman’s r= 0.56, n=14) and (B) CD86+ 636 
(*p=0.031, Spearman’s r=0.60, n=13) lymphocytes in HAM/TSP patients.  637 
 638 
Figure 4. Significant linear trend in Fas+ lymphocyte levels in PBMCs of HC, AC and 639 
HAM/TSP patients upon in vitro culture, and negative correlation with age of onset of 640 
HAM/TSP. (A) Fas levels were quantified by flow cytometry after 48h of in vitro culture. Fas+ 641 
lymphocytes (%) gradually increase (HC n=12 AC n=4 HAM n=12) upon infection (AC) and 642 
further upon disease progression to HAM/TSP (ANOVA, p=0.0005; post-test for linear trend, 643 
p<0.0001). (B) Lymphocyte Fas levels (after 48h of in vitro culture) quantified by flow 644 
cytometry (MFI) correlate negatively to age of onset in HAM/TSP patients (*p=0.019, 645 
Pearson’s r= - 0.69, n=11). 646 
 647 
Figure 5. Fashi cells are apoptosis-resistant in HAM/TSP patients. (A) Fas MFI (mean 648 
fluorescence intensity on a per-cell basis) negatively correlates to apoptosis (quantified as % 649 
annexin V+ cells) in lymphocytes of HAM/TSP patients (*p=0.012, Spearman’s r= - 0.63, 650 
n=15). (B) In the middle panel is a representative image of a non-apoptotic Fashi cell 651 
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(indicated by a red horizontal arrow). This Fashi cell is annexin V negative as visualized in 652 
the first panel and displays a normal nuclear morphology seen in the third panel. On the 653 
contrary, a Faslo cell in panel 1 (black vertical arrow), displays pronounced annexin V 654 
staining (panel 1) and is undergoing apoptosis, as evidenced by nuclear condensation, and 655 
is being engulfed by a macrophage. (C) In vitro Fas levels (MFI) and apoptosis (% of 656 
Annexin V+ cells) are compared between neuroinflammatory diseases HAM/TSP and MS 657 
(Mann Whitney test, *p<0.05). 658 
 659 
Figure 6. Fas surface expression correlates positively with in vitro and ex vivo 660 
lymphoproliferation in HAM/TSP patients. (A) In vitro Fas expression as measured by flow 661 
cytometry (MFI) correlates positively to lymphoproliferation quantified by [3H]-thymidine 662 
incorporation (*p=0.018, Pearson’s r=0.62, n=14). (B) Ex vivo Fas surface expression 663 
measured by flow cytometry (% and MFI) is significantly higher in proliferating (tetraploid, 4n) 664 
cells vs. diploid (2n) cells in HAM/TSP patients (Paired t test, p=0.0082 and p=0.0023 665 
respectively, n=5)  666 
 667 
Figure 7. In vitro Fas triggering with agonist anti-Fas mAb induces apoptosis in HAM/TSP 668 
and activates a molecular network linking apoptosis, proliferation and inflammation. (A) 669 
Agonist (ago) anti-Fas mAb but not antagonist (ant) anti-Fas mAb increased apoptosis 670 
(quantified by CellDeathPlus ELISA) in PBMCs upon in vitro treatment for 24h when 671 
compared to control (untreated) PBMCs. Treatment with anti-CD3 mAb was used as a 672 
positive control. (ANOVA, with Bonferroni’s post test *p<0.05, **p<0.01). (B) Top molecular 673 
network (score=34, linking cell-to-cell signalling, interaction, and cellular growth and 674 
proliferation) identified by Ingenuity pathway analysis (IPA) among 249 genes significantly 675 
up- and down-regulated (red and green, respectively) in PBMCs of HAM/TSP patients by in 676 
vitro treatment with agonist anti-Fas mAb.  677 
 678 
Figure 8. Model indicating the two-step increase in ex vivo lymphocyte Fas surface 679 
expression. First, following HTLV-1 infection, there is an increase in lymphocyte Fas 680 
expression (%) in AC. Second, upon progression to HAM/TSP, Fas expression is increased 681 
on a per-cell basis as Mean Fluorescence Intensity (MFI), (Figure 2A-B). In agreement with 682 
its role as a death receptor, Fas+ cells in HC are primed to follow the apoptotic pathway, 683 
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depicting nuclear condensation and cell blebbing, which is lost upon HTLV-1 infection (AC). 684 
In contrast, in HAM/TSP patients, Fashi cells are driven towards proliferation (Figure 7A-B). 685 
We recently discovered a genotype/phenotype interaction for the FAS -670 polymorphism 686 
with both apoptosis and proliferation in ATL patients and healthy controls (Khouri et al, 687 
submitted). This Fashi proliferating and chemotherapy-resistant leukemic phenotype is in 688 
agreement with the recently discovered CD4 Tscm hierarchical apex of ATL. The same FAS 689 
-670 polymorphism also determined CD4 Tscm levels in a genome-wide twin study, 690 
confirming our hypothesis (Khouri et al, submitted). Therefore, a genetically determined 691 
IFN/STAT1/FAS axis might help explain the proliferative, non-apoptotic phenotype in 692 
HAM/TSP suggesting CD4 Tscm as a pivotal factor not only in ATL but also in HAM/TSP 693 
pathogenesis. Considering STAT1 and FAS are in the HAM/TSP gene signature, our data 694 
further refine the data of Tattermusch et al.7 It is not unexpected that a Tscm phenotype is 695 
absent from the disease signature, since Tscm are rare (2-3%)47 and their genome-wide 696 
expression profile is intermediate between naïve and central memory T cells. However, 697 
Tscm cells have a Fashi, apoptosis-resistant and drug-resistant, proliferative phenotype, in 698 
agreement with their stem cell-like nature. Interestingly, the proliferating cells in HAM/TSP 699 
patients were almost exclusively Fashi, (Figure 6B), compatible with a Tscm phenotype. 700 
 701 
 702 
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 705 
 706 
 707 
  708 
Patient Age Gender Cohort Analysis
1 NA F BA Ex vivo flow cytometry
2 NA M BA Ex vivo flow cytometry
3 NA F BA Ex vivo flow cytometry
4 NA F BA Ex vivo flow cytometry
6 NA F BA Ex vivo flow cytometry
7 51 M BA Ex vivo and in vitro flow cytometry, In vitro apoptosis,  In vitro lymphoproliferation
8 40 M BA Ex vivo flow cytometry, In vitro apoptosis, In vitro lymphoproliferation
9 40 F BA Ex vivo flow cytometry, In vitro apoptosis, In vitro lymphoproliferation
10 63 F BA Ex vivo flow cytometry, In vitro apoptosis, In vitro lymphoproliferation
11 51 F BA Ex vivo and in vitro flow cytometry, In vitro apoptosis, In vitro lymphoproliferation
12 36 M BA Ex vivo and in vitro flow cytometry, In vitro apoptosis, In vitro lymphoproliferation
13 40 F BA Ex vivo and in vitro flow cytometry, In vitro apoptosis, In vitro lymphoproliferation
14 60 F BA Ex vivo and in vitro flow cytometry, In vitro apoptosis, In vitro lymphoproliferation
15 44 M BA Ex vivo flow cytometry,  In vitro apoptosis, In vitro lymphoproliferation
16 NA F BA Ex vivo flow cytometry,  In vitro apoptosis, In vitro lymphoproliferation
17 53 M BA Ex vivo and in vitro flow cytometry, In vitro apoptosis,  In vitro lymphoproliferation, Microarray
18 45 F BA Ex vivo and in vitro flow cytometry, In vitro apoptosis,  In vitro lymphoproliferation, Microarray
20 59 M BA Ex vivo and in vitro flow cytometry, In vitro apoptosis,  In vitro lymphoproliferation
21 60 F BA Ex vivo and in vitro flow cytometry, In vitro apoptosis,  In vitro lymphoproliferation
22 38 M BA In vitro lymphoproliferation
23 59 F BA In vitro lymphoproliferation
24 56 F BA In vitro flow cytometry, In vitro apoptosis, In vitro lymphoproliferation, Microarray
25 49 F BA In vitro apoptosis
26 57 M BA In vitro apoptosis
27 49 F BA In vitro flow cytometry, In vitro apoptosis  In vitro lymphoproliferation
28 60 M BA In vitro flow cytometry, In vitro apoptosis  In vitro lymphoproliferation, Microarray 
29 46 M BA In vitro apoptosis, In vitro lymphoproliferation, Microarray
31 50 M BA In vitro flow cytometry, In vitro apoptosis, In vitro lymphoproliferation, Microarray
32 50 F BA In vitro flow cytometry, In vitro apoptosis, In vitro lymphoproliferation, Microarray
33 62 F BA In vitro flow cytometry, In vitro apoptosis, In vitro lymphoproliferation
2569 27 F LI In vitro apoptosis
2570 50 F LI In vitro apoptosis
2574 35 F LI In vitro apoptosis
2817 64 F LI Ex vivo flow cytometry
2819 32 F LI Ex vivo flow cytometry
2821 63 F LI Ex vivo flow cytometry
2822 50 F LI Ex vivo flow cytometry
2823 64 M LI Ex vivo flow cytometry
SP5 32 F SP Ex vivo flow cytometry
SP6 65 F SP Ex vivo flow cytometry
SP7 62 F SP Ex vivo flow cytometry
SP8 47 F SP Ex vivo flow cytometry
SP26 35 M SP Ex vivo flow cytometry
SP30 72 M SP Ex vivo flow cytometry
SP32 27 M SP Ex vivo flow cytometry
SP36 52 F SP Ex vivo flow cytometry
SP46 61 F SP Ex vivo flow cytometry
Cohorts: BA Bahia, LI Lima, SP Sao Paulo
NA: Not available
Table 1. Patient information and sample use
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